Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, showing HCQ+AZ mortality relative risk RR 0.57,
p = 0.145.
Serrano et al., 9/22/2020, retrospective, Spain, Europe, peer-reviewed, 8 authors.
risk of death, 43.0% lower, RR 0.57, p = 0.14, treatment 6 of 14 (42.9%), control 6 of 8 (75.0%).